CLINICAL TRIALS PROFILE FOR METHERGINE

All Clinical Trials for METHERGINE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00858832 ↗	Reduction of Endometritis After Cesarean Section With the Routine Use of Methergine	Completed	University of South Florida	N/A	2008-12-01	Endomyometritis is an "infection in the uterus". It can occur in up to 1 out of 5 women having unplanned cesarean deliveries. Antibiotics are routinely given at the time of Cesarean delivery, but the infection in the uterus can still occur. When endomyometritis occurs it can prolong the woman's stay in the hospital after birth, slow down her recovery time at home, and increase medical costs. Methergine is a medication that is routinely used to stop uterine hemorrhage (excessive bleeding from the uterus) that sometimes happens after delivery. Methergine works by contracting (tightening) the uterus. These contractions also help the uterus to expel or remove parts of the placenta that increase the chance of developing a uterine infection. This research study is being done to learn if routine use of Methergine can lower the chances of developing a uterine infection after cesarean delivery. Half of the women in this study will receive Methergine for a few days during their hospitalization after cesarean delivery. The other half of the women will not routinely receive Methergine.
NCT00891150 ↗	Oxytocin to Decrease Blood Loss During Cesarean Section	Completed	American University of Beirut Medical Center	N/A	2012-07-01	The goal of this study is to determine the best dose of a drug called oxytocin, that is usually used to stop bleeding during a delivery, when used during a cesarean delivery. It will be administered during cesarean section in order to decrease the amount blood loss. The investigators are proposing to have 3 groups of subjects each given a different safe dose of oxytocin and then to assess the effectiveness of each regimens on the amount blood lost during cesarean sections.This will let use know which is the best lowest dose needed.
NCT02408965 ↗	Uterotonic Prophylaxis Trial	Completed	University of California, San Francisco	Phase 4	2015-03-01	Excessive bleeding after dilation and evacuation (D&E) requiring interventions is common, occurring in approximately 30% of cases at one large abortion-providing clinic. Uterotonic prophylaxis at the time of D&E, particularly with methylergonovine maleate (MM), is a common practice among D&E providers despite nearly no evidence for its efficacy. Finding ways to decrease excessive bleeding after D&E has the potential both to improve patient safety and to reduce costs of provider-initiated interventions. The investigators propose a randomized, controlled trial to investigate the efficacy of MM prophylaxis versus placebo in decreasing excessive bleeding measured by a composite outcome among women undergoing D&E at 20 to 24 weeks.
NCT02410759 ↗	Carbetocin Versus Ergometrine in the Management of Atonic Post Partum Haemorrhage (PPH) in Women Delivered Vaginally	Unknown status	Cairo University	Phase 3	2015-04-01	200 women will be randomly divided into 2 equal groups using computer generated random numbers. Group 1 will receive Carbetocin 100 µgm (Pabal® Ferring, UK) and group 2 will receive ergometrine 0.5mg (methergin®, Novartis, Switzerland).
NCT03303235 ↗	Intravenous Versus Intramuscular Administration of Methylergonovine for Uterine Contraction in Cesarean Sections	Withdrawn	Johns Hopkins University	Early Phase 1	2020-07-01	Insufficient uterine tone resulting in atony can potentiate hemorrhage and adverse outcomes for the parturient. Oxytocin is the first pharmacologic agent used, followed by methylergonovine, carboprost, and misoprostol. The American Congress of Obstetricians and Gynecologists (ACOG) recommends the sequential use of oxytocin, followed by methylergonovine, carboprost, misoprostol, then surgical intervention for cases of refractory uterine atony. Many studies have examined the effect and dosage of intravenous uterotonics, including oxytocin. Although there are anecdotal reports of using intravenous bolus or rapid infusion of methylergonovine, no randomized trial has compared efficacy and side effects of these two routes of administration. Investigators hypothesize that intravenous methylergonovine reduces the time to adequate uterine tone (the tone at which the uterus is adequately contracted to prevent atony after delivery of neonate), decreases the total dose of methylergonovine to contract the uterus, and therefore produces fewer side effects of hypertension, nausea, and vomiting. Reducing the time to achieve adequate uterine tone is likely to decrease postpartum hemorrhage.

Clinical Trial Conditions for METHERGINE

Condition Name

Condition Name for METHERGINE
Intervention	Trials
Postpartum Hemorrhage	3
Uterine Atony With Hemorrhage	1
Uterine Tone Disorders	1
Cesarean Section	1

Condition MeSH

Condition MeSH for METHERGINE
Intervention	Trials
Hemorrhage	7
Postpartum Hemorrhage	4
Uterine Inertia	2
Pregnancy Complications	1

Clinical Trial Locations for METHERGINE

Trials by Country

Trials by Country for METHERGINE
Location	Trials
United States	6
Egypt	2
Lebanon	1

Trials by US State

Trials by US State for METHERGINE
Location	Trials
New York	2
Iowa	1
Maryland	1
California	1
Florida	1

Clinical Trial Progress for METHERGINE

Clinical Trial Phase

Clinical Trial Phase for METHERGINE
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	2
Phase 1	1

Clinical Trial Status

Clinical Trial Status for METHERGINE
Clinical Trial Phase	Trials
Completed	5
Not yet recruiting	1
Recruiting	1

Clinical Trial Sponsors for METHERGINE

Sponsor Name

Sponsor Name for METHERGINE
Sponsor	Trials
Cairo University	2
American University of Beirut Medical Center	1
University of California, San Francisco	1

Sponsor Type

Sponsor Type for METHERGINE
Sponsor	Trials
Other	10